Results 121 to 130 of about 6,065 (241)

Short‐Term Daily Oral Administration of Cannabidiol Does Not Impact Rebound Tonometry Intraocular Pressure or Schirmer Tear Test Values in Healthy Adult Horses

Veterinary Ophthalmology, Volume 29, Issue 4, July 2026.
ABSTRACT Objective To assess the effect of orally administered cannabidiol (CBD) on TonoVet measured intraocular pressure (IOP) and Schirmer tear test I (STT) in horses. Animal Studied Horse. Procedure This was a masked, randomized, balanced cross‐over study of six healthy adult horses.
Kathryn Diehl, Colleen Sheridan, Rachel Reed   +2 more
wiley   +1 more source

Cannabigerol Alleviates Obesity‐Induced Mitochondrial Dysfunction by Cardiolipin Fatty Acid Remodeling

The FASEB Journal, Volume 40, Issue 11, 15 June 2026.
Graphical overview of the effects of the high‐fat, high‐sucrose (HFHS) diet regime and 2‐week cannabigerol (CBG) treatment on the intramuscular long‐chain fatty acids (LCFAs) trafficking and lipid metabolism, with subsequent implications for mitochondrial cardiolipin (CL) composition in the red gastrocnemius muscle.
Patrycja Bielawiec, Karolina Konstantynowicz‐Nowicka, Adrian Chabowski, Ewa Harasim‐Symbor   +3 more
wiley   +1 more source

Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

, 2019
The cannabinoid receptor type 1 (CB1R), a G protein-coupled receptor (GPCR), plays an essential role in the control of many physiological processes such as hunger, memory loss, gastrointestinal activity, catalepsy, fear, depression, and chronic pain ...
Ryszard Słomski, Klaudia Staszak, Szymon Hryhorowicz, Angelika Andrzejewska, Aleksandra Korcz, Marta Kaczmarek-Ryś, Magdalena Hryhorowicz   +6 more
core   +1 more source

Non‐Invasive Brain Targeted Delivery of Cannabidiol for Alleviating Neuroinflammatory Disease

Advanced Materials, Volume 38, Issue 31, 2 June 2026.
The glucose‐functionalized nanoparticles (GNPs) are developed for the brain‐targeted delivery of cannabidiol (CBD). GNPs bypass the blood‐brain barrier (BBB) via glucose transporter‐1 (GLUT‐1) and release CBD in response to reactive oxygen species (ROS).
Yibin Wang, Yundong Li, Xin Wang, Yaning Hou, Wei Deng, Meng Zheng, Yan Zou, Bingyang Shi   +7 more
wiley   +1 more source

Table_1_Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.docx

, 2019
In addition to its known actions as a non-selective cyclooxygenase (COX) 1 and 2 inhibitor, we hypothesized that indomethacin can act as an allosteric modulator of the type 1 cannabinoid receptor (CB1R) because of its shared structural features with the ...
Lesley A. Stevenson (2624434), Ganesh A. Thakur (638454), Robert B. Laprairie (315471), Ayat Zagzoog (7514204), Eileen M. Denovan-Wright (315472), Roger Pertwee (2272150), Kawthar A. Mohamed (7514201), Melanie E. M. Kelly (2624431)   +7 more
core   +1 more source

Plant‐Derived Melatonin Inhibits Bacterial Virulence via CpxA/R Two‐Component System

Advanced Science, Volume 13, Issue 32, 9 June 2026.
Plant‐derived melatonin is sensed by CpxAE48/T51, which inhibits the phosphorylation cascade transmission from CpxAH240 to CpxRD52, resulting in the inhibition of DNA‐binding capacity of CpxR and subsequent T3SS genes expression in Pst DC3000. ABSTRACT In defending against pathogens, plants deploy diverse secondary metabolites and signaling molecules ...
Jin‐Wei Wei, Wei Liu, Bili Cao, Dan Zhao, Chengqiang Wang, Xin Hou, Tangyuan Ning, Biao Gong   +7 more
wiley   +1 more source

Channel Dysfunction as the Basis for Comorbidities in Multiple Sclerosis and Depression

Archiv der Pharmazie, Volume 359, Issue 6, June 2026.
Ion channel remodelling induced by neuroinflammation in multiple sclerosis alters neuronal excitability and immune signalling, creating shared molecular pathways that link multiple sclerosis pathology to depression and reveal novel pharmacological targets.
Nicole Rychlik, Kay Jüngling, Sven G. Meuth, Thomas Budde, Marta Méndez‐Couz   +4 more
wiley   +1 more source

Synthesis of novel allosteric modulators for the cannabinoid CB1 receptors

, 2014
The CB1 cannabinoid receptor is a widely distributed G-protein coupled receptor in human central and peripheral system. It is the most abundant GPCR in the brain.
Damaraju, Venkata Surya Aparna
core  

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

British Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1595-1606, June 2026.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko, Titiaan E. Post, Pamela K. Strugala, Erica S. Klaassen, Linda E. Klumpers, Saco J. de Visser, Cristina Sempio, Jost Klawitter, Jules A. A. C. Heuberger, Geert J. Groeneveld   +9 more
wiley   +1 more source

Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators

, 2017
Introduction and Objectives: The traditional approach to target a particular receptor is to design compounds that bind to the same site as the endogenous ligand, the so-called ‘‘orthosteric site.’’ However, recently the search has shifted to ligands ...
Gómez-Cañas, María, Elguero, José, Morales, Paula, Jagerovic, Nadine, Hernández-Folgado, Laura, Cascio, Grazia, Goya, Pilar, Stevenson, Lesley A., Pazos, Ruth, Pertwee, Roger   +9 more
core   +1 more source